Comparative Pharmacology
Head-to-head clinical analysis: ALEVE versus ORUDIS KT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALEVE versus ORUDIS KT.
ALEVE vs ORUDIS KT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.
Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.
50 mg orally three times daily or 75 mg orally twice daily; maximum 300 mg/day.
None Documented
None Documented
Terminal elimination half-life is 12-17 hours; allows twice-daily dosing for steady-state concentrations.
Terminal elimination half-life: 2-4 hours (increased in elderly and renal impairment, up to 12 hours).
Renal (95% as unchanged drug and metabolites); biliary/fecal (5%)
Renal (approximately 60-80% as metabolites, <10% unchanged); biliary/fecal (approximately 20-35%).
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)